Early access to health products in France: Major advances of the French 'Conseil stratégique des industries de santé' (CSIS) to be implemented (modalities, regulations, funding)

Autor: Nicolas Albin, Frédéric Lavie, Lotfi Boudali, Céline Kauv, Natalie Hoog-Labouret, Anne-Céline Richard, Thibault de Chalus, Frédéric Chassagnol, Fabrice Meillier, Benjamin Mazaleyrat, Claire Le Jeunne, Olivier Blin, Adrien Monard, Brigitte Pouletty-Lefebvre, Mathilde Grande, Françoise Grudé, Estelle Fruchet, Jean-François Bergmann

Publikováno v: Thérapie
Thérapie, EDP Sciences-Depuis 2016, la revue Thérapie n’est plus publiée par EDP Sciences.> Therapies (Elsevier), 2019, 74 (1), pp.103-117. ⟨10.1016/j.therap.2018.12.002⟩

In a context of perpetual evolution of treatments, access to therapeutic innovation is a major challenge for patients and the various players involved in the procedures of access to medicines. The revolutions in genomic and personalized medicine, art

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca63055a7973a0c336636e78a59d4c0
https://doi.org/10.1016/j.therap.2018.12.002